Biotech's Smart Money: What Specialist Hedge Funds Bought in Q1 2026

Most 13F coverage chases the same handful of famous names — Berkshire, Pershing Square, Appaloosa. But there's a quieter corner of the filing universe that deserves more attention: the specialist biotech and healthcare hedge funds. Firms like Baker Bros. Advisors, OrbiMed, Deerfield Management, RTW Investments, and ADAR1 Capital Management live and breathe drug pipelines, FDA calendars, and clinical trial readouts. When their Q1 2026 filings landed in mid-May, they offered a rare window into where the most informed money in medicine is placing its bets.

Why biotech 13Fs punch above their weight

Generalist fund filings tell you about macro positioning and sentiment. Specialist biotech filings tell you something closer to expert opinion. These funds employ MDs, PhDs, and former FDA staffers whose entire job is handicapping clinical and regulatory outcomes. Research from BPIQ, which tracks 36 top biopharma-focused funds, has found in backtesting that the consensus and top holdings of these specialist funds have consistently outperformed the XBI biotech index. In their Q1 2026 analysis, the most widely held name appeared in the top-20 of 13 of the 36 funds tracked — a level of agreement that's unusual in a sector known for divergent views.

That's the same logic behind our overlap tool: when multiple sophisticated investors independently arrive at the same position, the signal strengthens. It applies doubly in biotech, where information asymmetry between specialists and the public is at its widest.

ADAR1's $40 million gene-editing bet

One of the more interesting new positions of the quarter came from ADAR1 Capital Management, which disclosed a brand-new stake in Beam Therapeutics (BEAM) — 1,446,375 shares acquired in an estimated $40 million trade during the January–March quarter, per its SEC filing dated May 15, 2026.

The timing looks prescient already. Beam traded at $27.93 when the filing dropped, up 61.9% over the prior year; by early July it had climbed above $34. The setup ADAR1 is betting on: Beam expects to file for FDA approval of risto-cel, its base-editing treatment for sickle cell disease, by late 2026, and plans to start pivotal trials for BEAM-302 — targeting a rare genetic liver disease — in the second half of the year. With roughly $1.2 billion in cash against a quarterly burn near $140 million, the company has runway to reach both catalysts.

ADAR1's broader book is a case study in specialist conviction. Its top holdings after Q1: Abivax (ABVX) at $155 million (a striking 9.4% of reportable assets), Protagonist Therapeutics (PTGX) at $105 million, Roivant Sciences (ROIV) at $91 million, and Immunovant (IMVT) at $67 million. Positions that size, in names that small, only happen when a fund believes it has genuine edge.

The catalyst-positioning game

What separates biotech funds from other 13F filers is how tightly their positioning maps to known future events. Drug approval decisions (PDUFA dates), trial readouts, and advisory committee meetings are scheduled in advance — and funds build or trim positions ahead of them based on their read of the odds. When you see a specialist fund initiate a large position two or three quarters ahead of a binary event, that's a probability assessment from people paid to be right about exactly this.

The standard caveats apply, amplified. 13Fs show quarter-end snapshots with a 45-day lag, they exclude short positions (biotech specialists short heavily), and a position may have been hedged or exited by the time you read the filing. Tracking position changes across quarters matters more here than in any other sector — a specialist fund cutting a position ahead of a readout is as informative as one building it.

How to use this signal

Three practical takeaways. First, follow the consensus, not the single stock pick: one fund's new position could be a hedge or a trade, but five specialist funds converging on a name is worth researching. Second, cross-reference holdings against the catalyst calendar — a big position with no near-term catalyst is a valuation bet; the same position ahead of a pivotal readout is a probability bet. Third, watch what the generalists do next: names like Beam that specialist funds accumulate early often show up in generalist portfolios two or three quarters later, and that migration is visible in our investor tracker.

Biotech remains the sector where following informed money offers the most edge — and the most risk. Binary outcomes cut both ways, and even the specialists get FDA surprises wrong. But if you want to know what the people with the deepest scientific benches think happens next in medicine, their 13Fs are public, free, and updated four times a year. The broader positioning picture across all the funds we track is on our macro consensus page.

---

Data sourced from public SEC 13F filings. Educational research only — not investment advice.